Navigation Links
Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis
Date:7/31/2014

BOSTON and NOTTINGHAM, England, July 31, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., and XenoGesis Ltd., have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage.  Molecular Profiles' pharmaceutical development services will be supported by XenoGesis' expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound's bioavailability.  This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates which have solubility issues during formulation development.

"We are very pleased to have struck this collaboration with the team at XenoGesis," said Frank Condella, President and Chief Executive Officer of Columbia Laboratories. "We have complementary service offerings which allow us to apply a science-driven, collective approach to overcome the complexities of challenging molecules. It also adds a vital pK service to our enabling technologies package.

"For us, this will build-upon the very successful drug development alliances we already have in place. We can now seamlessly offer a comprehensive service from initial drug discovery through to clinical supplies with best-in-class companies," concluded Mr. Condella.

XenoGesis was founded by its managing director, Richard Weaver Ph.D., after a 15-year career at AstraZeneca. The company specializes in studying research compounds from a chemical and biological perspective to inform clients on how they will behave in the body.

Dr. Weaver commented, "Combining our skills in DMPK with the chemical knowledge at Molecular Profiles will provide a solid platform to support clients.  We will be able to give them a better understanding of their compounds during pre-clinical work, which in turn, will reduce cost and provide a quicker route to market."

Working with leading drug development companies across the world, Columbia Laboratories' Molecular Profiles subsidiary specializes in advanced characterisation, pharmaceutical product development, clinical trials manufacturing and analytical support.  The company recently created a new enabling technologies team and invested in GMP hot melt extrusion (HME) technology at its clinical manufacturing facility to further enhance its expertise in the processing of difficult-to-progress molecules. 

Alongside its development capabilities, its MHRA-licensed site enables the company to manufacture a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds and controlled drugs.

About Columbia Laboratories
Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

About Molecular Profiles
Molecular Profiles Ltd., a wholly owned subsidiary of Columbia Laboratories, Inc., is a contract development and manufacturing organization (CDMO) that specializes in early phase pharmaceutical development. Its early phase services extend from pre-formulation and formulation development to clinical trial manufacturing, with specialist knowledge on developing challenging molecules and complex compounds.  Molecular Profiles is also renowned for its expertise and toolkit to analytically resolve some of the toughest issues during development and relating to intellectual property issues. The company's services are dedicated to pharmaceutical, biopharmaceutical and healthcare companies across the globe. For more information please visit www.molprofiles.co.uk

About XenoGesis
XenoGesis Limited, a contract research organization (CRO), specializes in expert DMPK/ADME laboratory services and interpretation and Drug Discovery consultancy.  The XenoGesis team has significant experience and a track record of delivering candidate drugs to man from their careers at AstraZeneca R&D Charnwood.  XenoGesis supports the Drug Discovery activities of Biotechnology and Pharmaceutical companies and academic units.  For more information please visit www.xenogesis.com 

Investor Relations Contact:
MBS Value Partners
Katja Buhrer or Betsy Brod
+212 661 7004
katja.buhrer@mbsvalue.com 


'/>"/>
SOURCE Columbia Laboratories, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cochlear Implants and BAHA Surgery at Columbia Asia Hospitals
2. What Can Healthcare Professionals Learn from Art? A Columbia University Physician Finds Answers at the Met
3. Columbia Asia Referral Hospital, Yeshwanthpur, Successfully Conducts HOLEP to Treat a 72-Year-old With Urology Disorder
4. Xenon Named Life Sciences Company of the Year by LifeSciences British Columbia
5. Columbia Laboratories Expands its Intellectual Property Portfolio Following Receipt of U.S. Patent
6. Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call
7. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
8. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
9. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
10. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
11. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  EIP Pharma, LLC ( www.eippharma.com ) ... neflamapimod (previously code named VX-745), with the results ... that demonstrated significant Alzheimer,s disease relevant pharmacological activity.  ... Study 303 (6-week treatment) are the subject of ... (CTAD) scientific conference in San Diego, ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... ... global chromatography market to grow at a CAGR of 5.42% during the ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/8/2016)... 8, 2016  Economic growth in the United States ... supply management executives in their December 2016 Semiannual Economic ... recovery that began in mid-2009, as indicated in the ... ® . The manufacturing sector is optimistic about growth ... manufacturing industries, and the non-manufacturing sector indicates that 14 ...
Breaking Medicine Technology:
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... ... 2016 , ... STAT courier is pleased to announce that due to customer ... are expanding their presence in Dallas. One of the most exciting parts for STAT ... to the Dallas and Forth Worth market. STAT takes pride in treating their employees ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Vida ... an $18M Series B led by Canvas Ventures . Other investors include Nokia ... scale its mobile platform to serve more consumers who are managing chronic conditions ...
Breaking Medicine News(10 mins):